Eton Pharmaceuticals, Inc. (ETON) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

And welcome to the IN Pharmaceuticals First Quarter 2025 Financial Results Conference call. At this time, all participants are in the listen-only mode. Following the formal remarks, we will open the call out for your questions. Please be advised that this call is being recorded at the company's request. At this time, I'd like to turn it over to David Kempa, Chief Business Officer at IN Pharmaceuticals. Please proceed. Thank you, Operator. Good afternoon, everyone, and welcome to Eaton's first quarter of 2025 conference call. This afternoon, we issued a press release that outlines the topics we plan to discuss on today's call. The release is available on our website, EatonPharma.com. Joining me on our call today, we have Shawn Brangelson, our CEO, James Gruber, our CFO, and Ipek Trinkas, our Chief Commercial Officer. In addition to taking live questions on today's call, we will be answering questions that are emailed to us. Investors can send their questions to investorrelations at eatonpharma.com. Before we begin, I would like to remind everyone that remarks made during this call may contain forward-looking statements and involve risks and uncertainties that could cause actual results to differ materially from those contained in these forward-looking statements. Please see the forward-looking statements disclaimer in our earnings release and the risk factors in companies' filings with the SEC. Now, I will turn the call over to our CEO, Sean Brangelson. Thank you, David. Good afternoon, everyone, and thank you for joining us today. If you were aware with us for our Investor Day in March, you heard about Eaton's transformational 2024, and I'm proud to say the momentum has continued into 2025. Our existing products are generating strong growth We recently added two high...